Results of Annual General Meeting

Diaceutics PLC
18 May 2023
 

18 May 2023

Diaceutics PLC

("Diaceutics" or "the Company")

Results of Annual General Meeting

Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharmaceutical industry, is pleased to announce that all resolutions proposed at its Annual General Meeting held earlier today, were duly passed.

The proxy votes received from shareholders in respect of each resolution are set out below and are available on the Company's website www.diaceutics.com

 

Resolution

For (excluding at Chair's discretion)

Against

Total votes cast

Withheld

 

 

Number of votes

%*

Number of votes

%*

 

Number of votes

1

Ordinary resolution to receive and consider the 2022 Financial Statements

60,055,552

100.00%

0

0.00%

60,055,552

 

Nil

 

2

Ordinary resolution to approve the directors' remuneration report

51,885,466

89.43%

6,131,086

10.57%

60,055,552

 

2,039,000

3

Ordinary resolution to re-elect Peter Keeling as a director

59,406,925

98.92%

648,627

1.08%

60,055,552

Nil

4

Ordinary resolution to re-elect Michael Wort as a director

55,788,593

92.89%

4,266,959

7.11%

60,055,552

Nil

5

Ordinary resolution to re-appoint Ernst & Young as auditors

60,055,552

100.00%

0

0.00%

60,055,552

 

Nil

6

Ordinary resolution to authorise the directors to determine the remuneration of the auditors

 

 

60,055,552

100.00%

0

0.00%

60,055,552

 

Nil

 

7

Ordinary resolution to authorise the directors to allot shares

 

60,055,552

100.00%

0

0.00%

60,055,552

 

Nil

 

8

Special resolution to authorise the directors to disapply pre-emption rights

 

60,055,202

99.9%

350

0.01%

60,055,552

 

Nil

9

Special resolution to authorise the directors to purchase own shares

59,976,122

100.00%

0

0.00%

60,055,552

 

79,430

 

*Percentage of votes cast excludes withheld votes

 

Enquiries:

Diaceutics PLC 


Peter Keeling, Chief Executive Officer

Via Alma PR 

Nick Roberts, Chief Financial Officer




Stifel Nicolaus Europe Limited (Nomad & Broker)

Tel: +44 (0)20 7710 7600

Ben Maddison, Nick Harland, Nick Adams




Alma PR

Tel: +44(0)20 3405 0205

Caroline Forde, Kieran Breheny, Matthew Young, Kinvara Verdon

diaceutics@almapr.co.uk


About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharmaceutical and life science companies with solutions and technology for the commercialisation of their precision medicines, enabled by the proprietary DXRX platform.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, utilising a global network of affiliate laboratories to deliver multiple pipelines of real‐world healthcare data insights, advisory services and innovative platform enabled solutions.

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Diaceutics (DXRX)
UK 100

Latest directors dealings